ArticleAnnals of the rheumatic diseases2008
Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists.
Article in Annals of the rheumatic diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.Annals of the rheumatic diseases · 2011Pooled it
- Predicting the outcome of ankylosing spondylitis therapy.Annals of the rheumatic diseases · 2011Trial
- [ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area].Zeitschrift fur Rheumatologie · 2013Article
- Agreement of Turkish physiatrists with the assessment in spondyloarthritis international society and the European league against rheumatism recommendations for the management of ankylosing spondylitis and rheumatoid arthritis.The open rheumatology journal · 2012Article
- [German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].Zeitschrift fur Rheumatologie · 2010Article
- [Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe].Zeitschrift fur Rheumatologie · 2009Article
- [Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis].Zeitschrift fur Rheumatologie · 2008Article
- Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic.Clinical rheumatology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTen ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS) were published in 2006.
objectives(a) To disseminate and (b) to evaluate conceptual agreement with, and (c) application of, these recommendations as well as (d) potential barriers to the application.
methodsA questionnaire was sent to rheumatologists in 10 countries. It included (a) the text of the recommendations; (b) rheumatologists' demographic variables; (c) two numerical rating scales from 1 to 10 for each recommendation: conceptual agreement with, and application of, the recommendation (10 indicates maximal agreement and maximal application); and (d) a list of potential barriers to the application of the recommendation. Statistical analysis included descriptive and multivariate analyses.
results7206 questionnaires were sent out; 1507 (21%) were returned. Of the 1507 answering rheumatologists, 62% were men, mean (SD) age 49 (9) years, and 34% had an academic position. Conceptual agreement with the recommendations was high (mean (SD) for all recommendations 8.9 (0.9)). Self-reported application was also high (8.2 (1.0)). The difference between agreement and application varied across recommendations and countries. The most pronounced discrepancies were reported for use of anti-tumour necrosis factor drugs in a few countries, with funding as the most commonly reported barrier for application of this recommendation.
conclusionThis large project has helped the dissemination of the ASAS/EULAR recommendations for the management of AS and shows that conceptual agreement with the recommendations is very high. The project also highlights inequalities in access to healthcare for European citizens with AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.